Morton and colleagues 1 have described the use of 0.75% ropivacaine for extradural anaesthesia, and in the process have clearly demonstrated the unsuitability of this agent as a test dose. The aim of an extradural test dose is to identify inadvertent i.v. or intrathecal catheter placement. It should have high sensitivity, but produce symptoms that are safe. Morton and colleagues inadvertently administered large i.v. doses of ropivacaine to two patients, despite negative test doses of ropivacaine 22.5 mg. This is not surprising, as Scott and colleagues 2 gave 10 mg min 91 i.v. for up to 15 min before producing symptoms. We do not, however, suggest the use of a larger dose of ropivacaine as a test dose. While this may increase sensitivity in identifying vascular cannulation, dangerously high spinal anaesthesia may result in intrathecal injection. Wahedi, Nolte and Klein 3 have produced safe spinal anaesthesia with 0.75% ropivacaine 22.5 mg in non-pregnant subjects, but there are no data to clarify a safe maximum intrathecal dose of ropivacaine in the obstetric population.
, proposed by Michels, Lyons and Hopkins. 4 However, Richardson and Wissler 5 described abrupt and life-threatening high spinal block after intrathecal test doses of only 45 mg of lignocaine in two patients. Michels' test dose is therefore clearly potentially dangerous.
In summary, we suggest that it is not possible to use a pure local anaesthetic test dose of sufficient dosage to identify the intravascular space without producing dangerously high spinal anaesthesia if injected intrathecally. We see no alternative but to use separate agents to identify inadvertent intravascular or intrathecal injection. Intrathecal catheter placement can be excluded easily using bupivacaine 10 mg. We remain unconvinced of the sensitivity and specificity of adding adrenaline to this test dose, and indeed have some concerns over its safety. Perhaps the addition of a potent short-acting opioid such as remifentanil warrants some investigation in this role ? The final logical but somewhat cumbersome suggestion is to follow a negative intrathecal test of bupivacaine with a second test of lignocaine 1 Sir,-We thank Drs Dresner, Adams and Klein for their interest in our article. We agree that ropivacaine 22.5 mg is an unsuitable test dose and we should have given greater emphasis to this in our article. But we do not think that this could have been predicted by the work of Scott and colleagues. 1 Our test dose was given over 20 s, considerably faster than the 10 mg min 91 used by Scott and colleagues. We do not agree that intrathecal catheter placement can be easily (our italics) excluded with bupivacaine 10 mg. Prince, Shetty and Miles 2 compared plain bupivacaine 8 mg by the subarachnoid and extradural routes, and could only discriminate reliably between the two routes by testing straight leg raising after 10 min. We do not agree with the suggestion of adding remifentanil to the test dose; this would seem to be exchanging the known risks and limitations of current test doses for the unknown.
Our own routine practice is to use lignocaine 80 mg as a "test dose". It is our opinion that this dose, if given rapidly, elicits symptoms of early systemic toxicity. We acknowledge that the addition of adrenaline 1 in 200 000 may increase sensitivity and specificity. The potential for high subarachnoid block is real but at least there is early clear evidence of inadvertent subarachnoid placement of the catheter. The crucial point about test doses, and one we continually emphasize to our trainees, is that a complacent attitude to a negative test dose is dangerous; a negative test dose does not completely exclude misplacement of the catheter. When an aspiration test and a test dose are negative, large doses of local anaesthetic must still be given slowly. We believe that this, and the lower toxicity of ropivacaine compared with bupivacaine, is why the two patients in our study who received accidental i.v. injections did not come to serious harm.
C 
Use of inhaled nitric oxide in the critically ill
Sir,-We read with interest the article by Cuthbertson, Stott and Webster on the increasing use of inhaled nitric oxide (iNO) in the critically ill. 1 We would disagree with their statement that there is no evidence that iNO improves patient outcome. One study in neonates with persistent pulmonary hypertension 2 demonstrated a reduction in the need for extracorporeal membrane oxygenation (ECMO) from 71% of patients in the control group to 40% in those receiving iNO (P:0.02). There was no difference in mortality between the two groups (7.1% in the control group vs 6.6% in the iNO group). A study of iNO in neonates with hypoxic respiratory failure 3 also demonstrated a decrease in the use of ECMO from 54.5% in controls to 38.6% in those receiving iNO (P:0.014). Again, mortality was similar (16.5% in the control group vs 14% in the iNO group). ECMO is expensive, invasive and unavailable in many centres. It is associated with morbidity, but has been shown to reduce mortality in term neonates with respiratory failure. 4 Using iNO to reduce the use of ECMO would seem appropriate. The children involved in studies of iNO are assessed neurodevelopmentally at 18-24 months, which may provide further support for the use of iNO. We accept that it would be wrong to extrapolate the studies directly to adults, although they indicate that there is a real role for iNO, and we await studies in older children and adults to resolve the place of iNO in these groups.
NO is stored as 1000 ppm in nitrogen, an asphyxiating mixture. In most units, iNO is added distally to the ventilator without oxygen monitoring. This is potentially dangerous. Providing less than 80 ppm of NO is used, as recommended by Cuthbertson Sir,-Our article was specifically on the use of inhaled nitric oxide (iNO) therapy in adults. Although the data regarding extracorporeal membrane oxygenation (ECMO) in neonates with respiratory distress syndrome and hypoxic respiratory failure are interesting, it does not change our statement that there is no evidence that iNO improves outcome. 1 2 Both studies quoted demonstrated a reduction in the requirement for ECMO but there was no change in mortality. It would be wrong to extrapolate the results in neonates to adult practice. Until further studies have been reported it would not seem appropriate to use iNO therapy merely to decrease the requirement for ECMO.
We have difficulty in understanding the points raised regarding NO delivery. Our article recommended continual monitoring of iNO therapy and a maximum dose. We did not recommend the use of any other cylinder except NO 1000 ppm in nitrogen. If the authors have 200-ppm cylinders designated for "use in calibration of monitoring equipment", we presume they would not be using them for patient care thus eliminating the danger of depression of
to which they refer. If iNO therapy and response to therapy are monitored closely and 1000-ppm cylinders are used, we feel that the risk of delivery of hypoxic gas mixtures is minimal.
We are pleased that Drs Whitehead and Baines are in agreement with us that the users of iNO therapy must appreciate all the incumbent risks and potential benefits. It was with this aim that we undertook our survey and made our recommendations based solely on adult practice.
B. H. CUTHBERTSON S. STOTT N. R. WEBSTER Anaesthesia and Intensive Care Department of Medicine and Therapeutics
University of Aberdeen Aberdeen 
Management of the airway and ventilation during resusitation
Sir,-In their recent article on the management of the airway and ventilation during resuscitation, Gabbott and Baskett mentioned an intubation aid used to confirm tracheal intubation called SCOTI. 1 I would like to point out that SCOTI (Sonomatic confirmation of tracheal intubation) was first marketed by Penlon in April 1995. This was in response to a need for a device capable of providing "instant" confirmation of tracheal intubation and against a background of ever increasing risk of litigation against anaesthetists. Although the device generated a great deal of interest, sales proved disappointing and at the end of 1996 a commercial decision was taken to discontinue marketing the SCOTI device. I believe a similar device continues to be available in the USA, although I am not aware of any devices working on a similar sonomatic principle being marketed elsewhere.
I trust this information is of interest and clarifies the current position regarding the SCOTI device.
C. RICHARDSON
Penlon Ltd Abingdon Oxon It is logical to assume that a decrease in peak intrapleural pressure to approximately 915 mm Hg from a normal value of 92.5 to 96 mm Hg while breathing normally through a tracheal tube of 9.0 mm internal diameter (id) reflects an increase in the work of breathing. But is it appropriate to extrapolate this observation and assume that a tracheostomy tube of size 8.0 or 9.0 mm id produces changes of similar magnitude? Work of breathing is dependent mainly on three factors: elastic resistance of the lung; non-elastic viscous resistance; and resistance to air flow. Increase in the work of breathing caused by airway instrumentation is generally believed to be a result of the increase in air flow resistance, even though one study could not confirm this. 3 While it is true that resistance to flow via a tube is dependent much more on internal diameter than on length, halving the length of a tube can reduce resistance by up to 50% 4 and doubling the length can double the resistance. 5 This holds true when flow is laminar. (The relationship between the length of a tube and resistance encountered is complex and there is no analogue for Poiseuille's law in the case of turbulent flow.) The length of a size 9.0 mm id tracheostomy tube is 10.5 cm (Portex, profile cuff type) compared with tracheal tubes cut at 21-24 cm. However, firm conclusions on the work of breathing in tracheostomized patients can only be made from clinical investigations, and not from simple application of mathematical formulae.
Another point worth mentioning is that if a patient starts speaking soon after deflation of a tracheostomy tube cuff without closing its external orifice, there may be a plug of mucus partially obstructing the tip of the tube. This is probably one of the causes of a dramatic improvement of any patient after removal of a tracheostomy tube or extubation ! S. K. Sir,-We appreciate Dr Kodakat's interest in our comments. The main objective of our letter was to emphasize that a tracheal tube or a tracheostomy tube increases the workload of breathing relative to the normal respiratory tract. The peak flow rate of a normal subject at rest is 0. To achieve normal ventilation, work is performed to overcome the elastic and frictional impedances of the lungs and chest wall. In the presence of increased resistance or decreased compliance, a greater swing in pleural pressure is required to achieve a given tidal volume, thus increasing the work of breathing. 3 Respiratory muscle fatigue does not occur during quiet breathing but develops when the ventilatory work load is increased. In patients with respiratory distress an inappropriately heightened respiratory drive places excessive stress on the respiratory muscle pump and predisposes to fatigue. 4 The peak flow in such patients could easily increase to 1 litre s
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, resulting in a markedly increased flow resistance with increasing flow rate in a non-linear manner, and could add substantially to the total work of breathing. 5 In this group of patients, intrapleural pressure could even be greater than 915 mm Hg. In contrast, in patients with severe respiratory muscle weakness, changes in intrapleural pressure could be smaller. However, both groups of patients may benefit from a reduction in respiratory resistance caused by cuff deflation.
We agree that for a given patient the work of breathing through a tracheostomy tube would be less compared with an equal diameter tracheal tube. There are no comparative studies of the effect of different sized tracheal tubes or tracheostomy tubes on intrapleural pressure in patients with respiratory failure. Our comment that "changes in intrapleural pressure caused by a size 8.0 or 9.0 mm id tracheostomy tube could be similar to that of a size 9.0 mm tracheal tube" was based on these factors. It 
Continuous intra-arterial blood-gas monitoring
Sir,-After reading the study on the usefulness of continuous intra-arterial blood-gas monitoring in patients undergoing thoracic procedures, 1 I feel it necessary to comment on some of the issues raised by the investigators.
The authors stated that the Paratrend 7 (PT7) blood-gas monitoring system has been validated by only one set of investigators in collaboration with the manufacturer. I would like to draw their attention to a multicentre study from North America 2 independently validating the PT7 system. Second, it is stated that a broad range of pH, PCO 2 and PO 2 values were not evaluated in the original studies. I would like to point out that a similar range of pH (7.1-7.57), PCO 2 (2.65-6.85 kPa) and PO 2 (8-68 kPa) values have been evaluated in an earlier study by Venkatesh, Clutton-Brock and Hendry. 3 The accuracy of the base excess and bicarbonate calculations are a function of the algorithm built into the blood-gas analyser and the monitor and accuracy of PCO 2 measurement. Dissociation in accuracy between the two methods for those two variables may be a reflection of differences in the algorithm or accuracy of the PCO 2 measurement.
While discussing the accuracy of the PT7 and blood-gas analyser, it is stated that "the accuracy and variability of blood-gas analysers are not known exactly". Studies by Hansen and colleagues, and Metger and colleagues have clearly demonstrated the bias and precision of blood-gas analysers when measuring blood-gas tensions in blood. 4 5 The authors have alluded to several factors which influence the accuracy of blood-gas analysis. Even controlling for the factors listed, the accuracy and reproducibility of blood-gas analysers remains an issue. It must be remembered that most blood-gas analysers do not use primary quality control material such as tonometered blood. This significantly limits any conclusions which can be drawn on the accuracy of an intravascular device. While studies such as these are important, clinical outcome and cost effectiveness studies are the ones which will influence the wholesale acceptance of intravascular sensing devices.
B. VENKATESH Critical Care Medicine Royal Brisbane Hospital
Queensland, Australia independently confirming the good clinical performance of the Paratrend 7 (PT7) multiparameter intra-arterial blood-gas monitoring system first described by this institution. [2] [3] [4] [5] Several ponts raised by the article require further discussion. The authors gave the impression that the sensor may be re-calibrated when inserted into a vessel by using data from a bench top blood-gas analyser. This is incorrect. Comparison between values obtained with the PT7 and bench top analyser can be made and the original calibration curve adjusted in the light of this comparison; this is somewhat different to re-calibration. When inserted into a vessel it is not possible to recalibrate the sensor without loss of sterility. The authors also stated that the PT7 can measure bloodgas variables at 37 ЊC or at patient (intravascular) temperature. In fact, all readings by the PT7 are made at patient (intravascular) temperature and then corrected, if required, to 37 ЊC, as opposed to bench top analysers which measure at 37 ЊC and correct to patient temperature. A subtle difference, but differences in the temperature correction algorithms may lead to discrepancies in displayed values.
With regard to the statistical evaluation of the data, there are three principal methods of describing relationships between continuous variables: (1) assessment of whether or not two variables are associated, that is if the values of one variable tend to be higher (or lower) for higher (or lower) values of the other variable, using the method known as correlation, presuming that at least one of the variables has a normal distribution in the study population; (2) assessment of whether the value of one variable to be predicted from any known value of the other variable, for which the technique of linear regression is used; and (3) assessment of the level of agreement between the values of the two variables by calculating the mean difference between readings (bias) and the degree of variability (precision). 6 For the study in question it is perhaps useful to know that high (or low) values from one monitor are reflected by high (or low) values from the other. Calculation of correlation coefficients and P values indicates how likely it is that a high (or low) value from one monitor is reflected by a high (or low) value from the other. No information on the level of agreement between the actual values displayed can be derived from this type of analysis. The PT7 monitor is designed to measure intra-arterial blood-gas tensions, not predict the values displayed by another monitor, thus calculation of regression statistics does not provide useful information on the performance of the sensor. Thus, results from correlation statistics should be interpreted with caution in this type of study and the technique of linear regression analysis should not be used.
The conclusion that the level of agreement between HCO 3 9 and base excess was relatively poor requires further comment. As part of an ongoing study in our department, 28 arterial blood samples were aspirated from patients in our intensive care unit and analysed simultaneously by a single operator using two bench top blood-gas analysers (ABL 300; Radiometer, Copenhagen, Denmark and NOVA Stat Profile Plus 9; NOVA Biomedical, Waltham, MA USA). , respectively. These values are of a similar magnitude to those obtained when comparing the PT7 system with the blood-gas analyser available for the study in question.
Finally, presentation of the levels of bias and precision in the units of the variables can be misleading. For example, for the above analysis the levels of bias and precision appear almost equal. However, the normal range for bicarbonate is numerically considerably larger than base excess and if bias and precision are calculated in percentage terms a different appraisal of the level of agreement is evident. For the data on bicarbonate, bias and precision were 91.59% and 16.92%, respectively. For the data on base excess, bias and precision were 943.25% and 206.72%, respectively. Therefore, when this type of data are presented, and values for bias and precision presented in the units of measurement, percentage bias and precision should also be quoted to give a more comprehensive assessment of the level of agreement.
S. J. GRAYSTONE Department of Anaesthesia and Intensive Care Queen Elizabeth Hospital University Hospitals NHS Trust Edgbaston, Birmingham
Sir,-Thank you for the opportunity to respond to the comments of Dr Graystone and Dr Venkatesh on our article. 1 They highlighted some important technical aspects. During use of the intraarterial sensor system, a correction of the Paratrend 7 (PT7) values on the basis of those obtained by in vitro blood-gas measurement is possible. This correction may be termed readjustment or recalibration, the difference being rather semantic. However, as described, no such correction was used in our study. This is important when rating the agreement of PT7 with laboratory in vitro blood-gas measurements, which is considered to be the gold standard, 2 and also when comparing results of our study with previous clinical work, where such corrections were used. [3] [4] [5] Furthermore, we agree that the algorithms built into the PT7 monitor and the bench top blood-gas analysers are crucial for the accuracy of all calculated parameters. Both the correction for measured blood-gas values from (intravascular) patient temperature to 37 ЊC (and vice versa) and calculation of bicarbonate and base excess rely on these algorithms. Therefore, a study on the accuracy of a new system, which provides these values, indirectly includes comparison of the algorithms incorporated in this new system with those of the in vitro blood-gas analyser. Interestingly, the accuracy of these calculated variables which are displayed on the PT7 monitor has not been clinically investigated previously. The conflict remains, that ". . . the clinical performance of an optode-based blood-gas monitor must be judged in comparison with the gold standard electrode-based blood gas analyzer, for which clinical performance cannot be specifically quantified". 2 At the time of preparation of our manuscript the PT7 sensor had been validated by only one group of authors. Since then Abraham, Gallagher and Fink 5 have reported on its clinical evaluation in different intensive care units. They followed a study design different from ours with special emphasis on continuous monitoring during a prolonged period of time. However, the results of their study may have been influenced by the fact that eight different bench top analysers from two different manufacturers were used in three different institutions. Furthermore, we stated that the PT7 system had been validated for limited bloodgas ranges only. This is true, as the ranges reported by Venkatesh, Clutton-Brock and Hendry 4 do not include clinically critical values of hypoxaemia and hypercapnia. However, we had the opportunity to measure some extreme values of arterial PO 2 (6.1 kPa) and PCO 2 (9.5 kPa) during thoracoscopic surgery.
Calculation of bias and precision is considered standard statistics for comparing this type of data. 6 In addition, linear regression analyses were performed to facilitate comparison with previous work. 7 It is important to note that both types of statistical analyses consistently revealed good agreement between PT7 derived and blood-gas analyser derived values for arterial PO 2 , PCO 2 and pH, and also consistently documented significant scattering between PT7 derived and blood-gas analyser derived values such as bicarbonate and base excess. 1 Finally, although clinical outcome and cost effectiveness studies are lacking in many other monitoring tools currently used in anaesthesia and intensive care, we agree fully that evidence-based, outcome-related data are mandatory for general acceptance of continuous intra-arterial blood-gas monitoring.
A 
